Álvaro González

Dr. Álvaro González

Service of Biochemistry, Clinica Universidad de Navarra, Av. Pío XII 36, 31008 Pamplona, Spain
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
MSMiguel F. Sanmamed
Miguel F. Sanmamed
SFSara Fernández-Landázuri
Sara Fernández-Landázuri
CRCarmen Rodríguez
Carmen Rodríguez
RZRuth Zárate
Ruth Zárate
Maria D. EscarioMaria D. Escario
Maria D. Escario
Álvaro GonzálezÁlvaro González
Álvaro González
Background: Around 50% of cutaneous melanomas harbor the BRAFV600E mutation and can be treated with BRAF inhibitors. DNA carrying this mutation can be released into circulation as cell-free BRAFV600E (cfBRAFV600E). Droplet digital PCR (ddPCR) is an analytically sensitive technique for quantifying small concentrations of DNA. We studied the plasma concentrations of cfBRAFV600E by ddPCR in patients with melanoma during therapy with BRAF inhibitors. Methods: Plasma concentrations of cfBRAFV600E were measured in 8 controls and 20 patients with advanced melanoma having the BRAFV600E mutation during treatment with BRAF inhibitors at baseline, first month, best response, and progression. Results: The BRAFV600E mutation was detected by ddPCR even at a fractional abundance of 0.005% in the wild-type gene. Agreement between tumor tissue BRAFV600E and plasma cfBRAFV600E was 84.3%. Baseline cfBRAFV600E correlated with tumor burden (r = 0.742, P < 0.001). cfBRAFV600E concentrations decreased significantly at the first month of therapy (basal median, 216 copies/mL; Q1–Q3, 27–647 copies/mL; first response median, 0 copies/mL; Q1–Q3, 0–49 copies/mL; P < 0.01) and at the moment of best response (median, 0 copies/mL; Q1–Q3, 0–33 copies/mL; P < 0.01). At progression, there was a significant increase in the concentration of cfBRAFV600E compared with best response (median, 115 copies/mL; Q1–Q3, 3–707 copies/mL; P = 0.013). Lower concentrations of basal cfBRAFV600E were significantly associated with longer overall survival and progression-free survival (27.7 months and 9 months, respectively) than higher basal concentrations (8.6 months and 3 months, P < 0.001 and P = 0.024, respectively). Conclusions: cfBRAFV600E quantification in plasma by ddPCR is useful as a follow-up to treatment response in patients with advanced melanoma.

26 April 2012 in Critical Reviews in Clinical Laboratory Sciences
Verified
Journal Article
Closed access
Álvaro GonzálezÁlvaro González
Álvaro González
VRVera Rebmann
Vera Rebmann
JLJoel LeMaoult
Joel LeMaoult
PHPeter A. Horn
Peter A. Horn
ECEdgardo D. Carosella
Edgardo D. Carosella
EAEstíbaliz Alegre
Estíbaliz Alegre
Human leukocyte antigen G (HLA-G) is a non-classical major histocompatibility complex (MHC) class I molecule that, through interaction with its receptors, exerts important tolerogenic functions. Its main physiological expression occurs in placenta where it seems to participate in the maternal tolerance toward the fetus. HLA-G has been studied as a marker of pregnancy complications such as abortion or pre-eclapmsia. Although HLA-G is not expressed in most adult tissues, its ectopic expression has been observed in some diseases such as viral infections, autoimmune disorders, and especially cancer. HLA-G neo-expression in cancer is associated with the capability of tumor cells to evade the immune control. In this review, we will summarize HLA-G biology and how it participates in these physiopathological processes. Special attention will be paid to its role as a diagnostic tool and also as a therapeutic target.

1 February 2016 in Clinica Chimica Acta
Verified
Journal Article
Closed access
EAEstíbaliz Alegre
Estíbaliz Alegre
LZLeyre Zubiri
Leyre Zubiri
JGJose Luis Perez Gracia
Jose Luis Perez Gracia
MGMaría González-Cao
María González-Cao
LSLourdes Soria
Lourdes Soria
Álvaro GonzálezÁlvaro González
Álvaro González

13 January 2020 in Nature Cancer
Verified
Journal Article
Open access
PDF file
DADaniel Ajona
Daniel Ajona
SOSergio Ortiz-Espinosa
Sergio Ortiz-Espinosa
TLTeresa Lozano
Teresa Lozano
FEFrancisco Exposito
Francisco Exposito
ACAlfonso Calvo
Alfonso Calvo
Ruben PioRuben Pio
Ruben Pio
Harnessing the immune system by blocking the programmed cell death protein 1 (PD-1) pathway has been a major breakthrough in non-small-cell lung cancer treatment. Nonetheless, many patients fail to respond to PD-1 inhibition. Using three syngeneic models, we demonstrate that short-term starvation synergizes with PD-1 blockade to inhibit lung cancer progression and metastasis. This antitumor activity was linked to a reduction in circulating insulin-like growth factor 1 (IGF-1) and a downregulation of IGF-1 receptor (IGF-1R) signaling in tumor cells. A combined inhibition of IGF-1R and PD-1 synergistically reduced tumor growth in mice. This effect required CD8 cells, boosted the intratumoral CD8/Treg ratio and led to the development of tumor-specific immunity. In patients with non-small-cell lung cancer, high plasma levels of IGF-1 or high IGF-1R expression in tumors was associated with resistance to anti-PD-1–programmed death-ligand 1 immunotherapy. In conclusion, our data strongly support the clinical evaluation of IGF-1 modulators in combination with PD-1 blockade.

1 June 2014 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Closed access
EAEstíbaliz Alegre
Estíbaliz Alegre
MSMiguel F. Sanmamed
Miguel F. Sanmamed
CRCarmen Rodriguez
Carmen Rodriguez
OCOmar Carranza
Omar Carranza
SMSalvador Martín-Algarra
Salvador Martín-Algarra
Álvaro GonzálezÁlvaro González
Álvaro González
Context .—Malignant melanoma is an aggressive tumor that produces exosomes, which contain microRNAs (miRNAs) that could be of utility in following tumoral cell dysregulation. MicroR-125b is a miRNA whose down-regulation seems to be implicated in melanoma progression. Objective .—To analyze miR-125b levels in serum, and in exosomes obtained from serum, from patients with advanced melanoma. Design .—Serum samples were obtained from 21 patients with advanced melanoma, from 16 disease-free patients with melanoma, and from 19 healthy volunteers. Exosomes were isolated from serum by precipitation, and miR-16 and miR-125b levels were quantified by real-time polymerase chain reaction. Results .—MicroR-16, but not miR-125b, was detected in all samples, and miR-16 levels were significantly higher in serum than they were in exosomes. MicroR-16 expression levels did not differ significantly between the 2 groups (patients with melanoma and healthy donors). There was a significant relationship between miR-125b and miR-16 levels in exosomes. Additionally, miR-125b levels in exosomes were significantly lower in patients with melanoma compared with disease-free patients with melanoma and healthy controls. Conclusions .—Exosomes can provide a suitable material to measure circulating miRNA in melanoma, and miR-16 can be used as an endogenous normalizer. Lower levels of miR-125b in exosomes obtained from serum are associated with advanced melanoma disease, probably reflecting the tumoral cell dysregulation.

23 March 2019 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
PDF file
MMMónica Macías
Mónica Macías
VRVera Rebmann
Vera Rebmann
BMBeatriz Mateos
Beatriz Mateos
NVNerea Varo
Nerea Varo
JPJose Luis Perez-Gracia
Jose Luis Perez-Gracia
Álvaro GonzálezÁlvaro González
Álvaro González
Background: Exosomes are nanovesicles released by cells that can be detected in blood. Exosomes contain several molecules, such as cytokines that have potential utility as disease biomarkers. The aim of the present work is to compare six different commercial kits suitable for the clinical laboratory in relation to the efficiency and purity of exosome isolation, and their effect in subsequent cytokines analysis. Methods: Serum exosomes were obtained from 10 volunteers using six commercial kits: exoEasy, ExoQuick, Exo-spin, ME kit, ExoQuick Plus and Exo-Flow. Exosome concentrations and size distributions were quantified by nanoparticle tracking analysis. Exosome markers CD63, CD9 and TSG101 were determined by Western blot. ApoB and albumin were measured using nephelometry. S100A9, CXCL5 and CXCL12 were measured using a Luminex assay. Results: The concentration of particles obtained between different kits varied by a factor of 100. There was no correlation in particle concentrations extracted between different kits, except between ExoQuick and Exo-Flow. The highest exosome purity was achieved with ExoQuick Plus and exoEasy, while the lowest were achieved with ME and ExoQuick. Albumin was present in all exosome extracts analyzed and ApoB in all except those extracted with Exo-Flow and ME. Cytokine detection varied depending on the purification kit used and there was no correlation in cytokine concentrations between samples obtained with different kits. Conclusions: Both the sample and the type of commercial kit used affect the efficiency and purity of exosome isolation. In addition, the exosome purification method deeply affects the capability to detect and quantify cytokines.